Randomized clinical trials (RCTs) should not be the sole informant of health economic decisions
- A real-world study in ovarian cancer has described median overall survival data shorter than those described in randomized clinical trials
- This data emphasises the differences between the clinical outcomes of patients from RCTs and those from a real life setting
- Real-world evidence can serve a important purpose in complementing the data generated by RCTs and address data gaps
Click here for the article published in the International Journal of Gynaecological Cancer
SVMPharma’s chart note reviews provide the insights you need to meet your business needs. Click here to learn more.
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.